Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Targeting B cells in systemic lupus erythematosus: not just déjà vu all over again. | Available online http arthritis-research.eom content 8 3 108 Commentary Targeting B cells in systemic lupus erythematosus not just déjà vu all over again Robert Eisenberg Division of Rheumatology Department of Medicine University of Pennsylvania School of Medicine 756 BRBII III 421 Curie Boulevard Philadelphia PA 19104-6160 USA Corresponding author raemd@mail.med.upenn.edu Published 15 May 2006 Arthritis Research Therapy 2006 8 108 doi 10.1186 ar1967 This article is online at http arthritis-research.com content 8 3 108 2006 BioMed Central Ltd See related research article by Dorner et al. http arthritis-research.com content 8 3 R74 Abstract Epratuzumab anti-CD22 is a humanized monoclonal antibody that recognizes a pan-B-cell marker. It potentially downregulates B cell activity through negative signaling as well as depleting B cells moderately. The uncontrolled series discussed by Dorner and colleagues in this issue of Arthritis Research Therapy suggests that epratuzumab may be safe and efficacious for systemic lupus erythematosus. A randomized controlled trial is currently active to test this possibility. The article by Dorner and colleagues in the current issue of Arthritis Research Therapy describes an open-label phase I trial of the B cell-specific humanized monoclonal antibody epratuzumab anti-CD22 in 14 patients with moderately active systemic lupus erythematosus SLE one or more British Isles Lupus Assessment Group BILAG Bs in all patients except one 1 . Clinical improvement was seen in all patients by 7 to 10 weeks after initiation of the 6-week course of four infusions. The infusions were generally well tolerated and overall no repeated safety signals were seen. Other than a modest and inconsistent fall in B cell counts in peripheral blood no laboratory parameters were affected including autoantibodies and complement. These data are supportive of the rationale for the currently active randomized controlled trial of epratuzumab to establish efficacy in SLE. .